{"entity":{"id":"nct06179524","kind":"trial","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","aka":[],"tldr":"A phase 2 trial of CAR-T-19 cell injection in acute lymphoblastic leukaemia, run by Beijing Yongtai Ruike Biotechnology Company Ltd, now recruiting.","summary":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL is a phase 2 interventional study registered as NCT06179524 by Beijing Yongtai Ruike Biotechnology Company Ltd, with 100 participants planned, started 2024-01-03 and due to reach its primary completion in 2025-06-30. Interventions recorded: CAR-T-19 cell injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06179524","url":"https://clinicaltrials.gov/study/NCT06179524"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06179524","phase":"2","setting":"Phase II Clinical Study of CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (inclusive)","sponsor":"Beijing Yongtai Ruike Biotechnology Company Ltd","enrolled":100,"outcomes":[]},"route":"/trials/nct06179524/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}]}}